Compare Funko Inc (FNKO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Incyte Corporation — how do they compare? Funko Inc trades at $5.75 (market cap $315.21M), while Incyte Corporation trades at $116.13 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 72.9× Funko Inc's market cap. Which is the better fit depends on your goals.
| FNKO | INCY | |
|---|---|---|
Market Cap | $315.21M | $22.99B |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $118.52 |
52-Week Low | $2.46 | $67.38 |
Enterprise Value | $560.25M | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.55, down 2.46% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/S ratio of 0.34 and strong gross margins near 40%, but negative net income and ROE. Recent quarters have seen earnings beats against expectations, and analyst sentiment leans positive with a 42.86% buy rating and no sell recommendations. News highlights new product launches and a strong Q1 2026 report.
The outlook balances product-driven revenue potential against persistent profitability challenges. Investment opportunity lies in the low valuation multiple and recent earnings momentum, but risks include sustained negative margins, high debt levels, and volatile cash flows from operations.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
